These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2040033

  • 1. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES, Baselga J, Smart TB, Magill GB, Markman M, Ranhosky A.
    Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
    [Abstract] [Full Text] [Related]

  • 2. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V, Van Oosterom A, Mouridsen HT, Cheix F, Somers R, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
    Kurzrock R, Yap BS, Plager C, Papdopoulos N, Benjamin RS, Valdivieso M, Bodey GP.
    Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860
    [Abstract] [Full Text] [Related]

  • 5. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC, Markman M, Cleary S, Howell SB.
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M, Chan TC, Cleary S, Howell SB.
    Cancer Chemother Pharmacol; 1987 Jun; 19(1):80-3. PubMed ID: 3815730
    [Abstract] [Full Text] [Related]

  • 7. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 8. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR, Mulder JH, Rümke P, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 10. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May 15; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 May 15; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 12. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA, Ardalan B, Multhauf P, Chan C, Staples R, Green L, Browning S, Carr BI, Chang FF, Thayer W.
    Med Pediatr Oncol; 1983 May 15; 11(3):162-3. PubMed ID: 6222250
    [Abstract] [Full Text] [Related]

  • 13. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun 15; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 14. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Jun 15; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 15. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG, Davis TE, Falkson G, Keller AM.
    Am J Clin Oncol; 1982 Dec 15; 5(6):627-9. PubMed ID: 7165004
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 17. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982 Aug 15; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 20. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ.
    Pharmacol Ther; 1990 Aug 15; 48(3):371-80. PubMed ID: 2084707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.